-

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2022 results after the financial markets close on Wednesday, February 22, 2023. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2022 financial and operating results.

A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. To access the call by phone, please use this link (https://register.vevent.com/register/BI676b1bca7fca4eeaa60be7e9c39f206b) and you will be provided with dial-in details, including a personal pin.

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions
$Cashtags

Contacts

Media Contact:
858-255-6388
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID) technology. This approval adds compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor and expands the t:slim X2 system’s indications for use to people with type 1 diabetes during pregnancy and to adults with...

Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--Jeannette Bankes named President and CEO of Tandem Diabetes Care in planned transition as John Sheridan Retires After Over a Decade of Service...

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.) Gross margin of 57%, up 270 basis points compared to third quarter 2025 Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pu...
Back to Newsroom